BioSpace News Archive

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the 9th Annual SVB Leerink Global Healthcare Conference February 25-27, 2020 at the Lotte New York Palace in New York, NY, USA.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Cowen 40th Annual Health Care Conference on Wednesday, March 4, 2020.

Company Anticipates Earlier Than Expected Preliminary Data Readout in August 2020

The Trendlines Group Ltd., is pleased to announce that its newly-formed fund, Trendlines Agrifood Fund Pte. Ltd., has made its first investment, investing in Equinom Ltd, a seed breeding technology business..

BRIDGEWATER, N.J. , Feb. 19, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the 9 th Annual SVB Leerink Global Healthcare Conference in New York, NY on We

REDWOOD CITY, Calif. , Feb. 19, 2020 /PRNewswire/ -- Bolt Biotherapeutics, a private biotechnology company focused on using its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the immune system to treat cancer, today announced that Randall C. Schatzman , PhD., Chief Executive Officer, will present at the SVB Leerink 9 th Annual Global

Cleveland Clinic, Mayo Clinic, St. Jude Children’s Research Hospital Claim Top Spots

Feb. 19, 2020 13:00 UTC Presentation and webcast to take place at 9:00 a.m. ET on February 26 CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that management will be presenting at the SVB Leerink 9th Annual Global Healthcare Conference in New York City on February 26,

Feb. 19, 2020 13:00 UTC Industry veteran to helm newly created position as H3 advances oncology pipeline CAMBRIDGE, Mass.--( BUSINESS WIRE )-- H3 Biomedicine, Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the appointment of Antonio Gualberto, MD, PhD, to the position of Chief Medical Officer (CMO). Dr. Gualberto will oversee global clinical research & development for the H3 pipeline of clinical sta

SAN DIEGO , Feb. 19, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical stage targeted oncology company, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 26,712 shares of common stock and an aggregate of 16,659 restricted stock units (“RSUs”) to three new employees. Each stock option has an exercise pric